



PROFICIENCY RESULTS FROM YOUR PEERS AT EULAR 2018 AND BEYOND

BACKGROUND

At our **EULAR 2018** symposium, we discussed:




HOW CYTOKINES
AFFECT RA



DISEASE
MONITORING



WHEN TO SWITCH
VS CYCLE DRUGS



SHARED DECISION
MAKING (SDM)


Here is how your peers performed in 2018 on these topics:

611
TOTAL
LEARNERS

202
EULAR 2018


409
ONLINE

71%
PHYSICIANS




>1500

RA PATIENT
ENCOUNTERS/WEEK




WHAT LEARNERS DID WELL ON...




67%

KNEW WHEN TO SWITCH
DRUG CLASSES IN A CASE OF
SECONDARY NONRESPONSE



71%

UNDERSTOOD THE
CONNECTION BETWEEN
IL-6 AND FATIGUE




87%

WERE ABLE TO IDENTIFY
IMPORTANT ELEMENTS OF SDM

SCAN HERE FOR
AUDIO GUIDED POSTER




WHAT LEARNERS STRUGGLED WITH...




12%

COULD DEFINE
THE ACR/EULAR
REMISSION CRITERIA




45%

KNEW WHETHER TO
SWITCH VS CYCLE DRUG
CLASSES IN A CASE OF
PRIMARY NONRESPONSE




...AND REPORTED ONLY
BEING 50% CONFIDENT
AS TO WHEN TO DO SO



51%

KNEW THE CORRECT
IL-6 CYTOKINE
SIGNALING PATHWAY




54%


WERE AWARE IL-6
WAS RELATED TO FATIGUE,
PAIN, DEPRESSION,
AND ANEMIA

WHERE TO GO FROM HERE...


CONTINUED EDUCATIONAL NEEDS



EFFECTS OF IL-6
INHIBITORS ON EXTRA-
ARTICULAR DISEASE IN
RA PATIENTS



WHEN TO CYCLE AND
WHEN TO SWITCH
DRUG CLASSES



BUILDING CONFIDENCE
IN HOW TO CHOOSE
THE NEXT LINE OF
THERAPY